Overview

Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure

Status:
Terminated
Trial end date:
2017-04-03
Target enrollment:
Participant gender:
Summary
The purpose of the study was to evaluate the safety, tolerability and pharmacokinetics of an intravenous infusion of serelaxin on top of standard of care therapy, in pediatric patients with acute heart failure (AHF)
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals